Alwaiswin Pharma

Alwaiswin Pharma is a clinical-stage biopharmaceutical company based in Hangzhou, China, dedicated to the development of innovative precision oncology treatments. The company focuses on targeting key drivers of cancer, particularly the KRAS signaling pathway, which has historically been considered difficult to target. Its lead program, ALW-001, is a highly selective KRAS G12C inhibitor currently in Phase 1/2 clinical trials for patients with advanced solid tumors. Beyond its lead candidate, Alwaiswin is advancing a pipeline of small molecule inhibitors designed to overcome resistance mechanisms in cancer. The company is backed by prominent life science investors, including Qiming Venture Partners and Lilly Asia Ventures.